Literature DB >> 19708058

Assessing disease activity in ulcerative colitis: patients or their physicians?

Dan Turner1, Anne M Griffiths, David Mack, Anthony R Otley, Cynthia H Seow, A Hillary Steinhart, Mark S Silverberg, Jeffrey Hyams, Gordon H Guyatt.   

Abstract

BACKGROUND: We aimed to determine the optimal approach to assess disease activity (i.e., biological inflammation) in ulcerative colitis (UC) by comparing patients' and physicians' rating of the disease.
METHODS: This was a prospective, multicenter, double-cohort study. The first cohort was composed of 94 children with UC (parent proxy when required) and their physicians who provided independent clinical report and global assessment of disease, rated on a 100 mm visual analog scale. Constructs of disease activity (including mucosal inflammation, laboratory tests, Mayo score, and the Pediatric UC Activity Index), were scored by an independent blinded physician and used to compare validity of the assessment. Of the 94 children, 43 were seen at a follow-up visit and provided a global rating of change in disease activity. To ascertain whether age influences assessment accuracy, a second cohort of 86 adult UC patients were analyzed in a similar way.
RESULTS: In both cohorts the physician global assessment had higher correlations with all constructs of disease activity than did the patient' global assessment (for colonoscopic score r = 0.76 vs. r = 0.29, P = 0.002). Even with abdominal pain, a subjective item, the physician's rating had higher correlation than the patient's rating. Similarly, the physician rating of change better reflected change in disease activity than that of the patient rating.
CONCLUSIONS: For indirect measurement of biological activity on the basis of symptoms and signs, clinician assessments are superior to those of patients. Patient assessments, physician assessments, and direct measurement of disease activity provide complementary information in clinical research.

Entities:  

Mesh:

Year:  2010        PMID: 19708058     DOI: 10.1002/ibd.21088

Source DB:  PubMed          Journal:  Inflamm Bowel Dis        ISSN: 1078-0998            Impact factor:   5.325


  12 in total

1.  What is the value of incorporating tear osmolarity measurement in assessing patient response to therapy in dry eye disease?

Authors:  Francisco Amparo; Yiping Jin; Pedram Hamrah; Debra A Schaumberg; Reza Dana
Journal:  Am J Ophthalmol       Date:  2013-09-21       Impact factor: 5.258

2.  Abdominal pain in ulcerative colitis.

Authors:  Matthew D Coates; Mayank Lahoti; David G Binion; Eva M Szigethy; Miguel D Regueiro; Klaus Bielefeldt
Journal:  Inflamm Bowel Dis       Date:  2013-09       Impact factor: 5.325

3.  The Feasibility of Measuring Sleep and Circadian Characteristics in Adults with Inflammatory Bowel Disease.

Authors:  Samantha Conley; Deborah D Proctor; Vanessa Lehner; Sangchoon Jeon; Nancy S Redeker
Journal:  West J Nurs Res       Date:  2020-06-09       Impact factor: 1.967

4.  Feasibility and validity of the pediatric ulcerative colitis activity index in routine clinical practice.

Authors:  Jennifer L Dotson; Wallace V Crandall; Peixin Zhang; Christopher B Forrest; L Charles Bailey; Richard B Colletti; Michael D Kappelman
Journal:  J Pediatr Gastroenterol Nutr       Date:  2015-02       Impact factor: 2.839

5.  Oral Vancomycin, Ursodeoxycholic Acid, or No Therapy for Pediatric Primary Sclerosing Cholangitis: A Matched Analysis.

Authors:  Mark R Deneau; Cara Mack; Douglas Mogul; Emily R Perito; Pamela L Valentino; Achiya Z Amir; Matthew DiGuglielmo; Laura G Draijer; Wael El-Matary; Katryn N Furuya; Nitika Gupta; Jessica T Hochberg; Simon Horslen; M Kyle Jensen; Maureen M Jonas; Nanda Kerkar; Bart G P Koot; Trevor J Laborda; Christine K Lee; Kathleen M Loomes; Mercedes Martinez; Alexander Miethke; Tamir Miloh; Saeed Mohammad; Nadia Ovchinsky; Girish Rao; Amanda Ricciuto; Pushpa Sathya; Kathleen B Schwarz; Uzma Shah; Ruchi Singh; Bernadette Vitola; Andréanne Zizzo; Stephen L Guthery
Journal:  Hepatology       Date:  2021-03       Impact factor: 17.425

6.  Modeling Endoscopic Improvement after Induction Treatment With Mesalamine in Patients With Mild-to-Moderate Ulcerative Colitis.

Authors:  Christopher Ma; Jenny Jeyarajah; Leonardo Guizzetti; Claire E Parker; Siddharth Singh; Parambir S Dulai; Geert R D'Haens; William J Sandborn; Brian G Feagan; Vipul Jairath
Journal:  Clin Gastroenterol Hepatol       Date:  2020-12-03       Impact factor: 11.382

7.  Recurrence of Primary Sclerosing Cholangitis After Liver Transplant in Children: An International Observational Study.

Authors:  Mercedes Martinez; Emily R Perito; Pamela Valentino; Cara L Mack; Madeleine Aumar; Annemarie Broderick; Laura G Draijer; Eleonora D T Fagundes; Katryn N Furuya; Nitika Gupta; Simon Horslen; Maureen M Jonas; Binita M Kamath; Nanda Kerkar; Kyung Mo Kim; Kaija-Leena Kolho; Bart G P Koot; Trevor J Laborda; Christine K Lee; Kathleen M Loomes; Tamir Miloh; Douglas Mogul; Saeed Mohammed; Nadia Ovchinsky; Girish Rao; Amanda Ricciuto; Alexandre Rodrigues Ferreira; Kathleen B Schwarz; Vratislav Smolka; Atsushi Tanaka; Mary E M Tessier; Venna L Venkat; Bernadette E Vitola; Marek Woynarowski; Melissa Zerofsky; Mark R Deneau
Journal:  Hepatology       Date:  2021-09-09       Impact factor: 17.298

8.  Sleep Characteristics and Rest-Activity Rhythms Are Associated with Gastrointestinal Symptoms Among Adults with Inflammatory Bowel Disease.

Authors:  Samantha Conley; Sangchoon Jeon; Vanessa Lehner; Deborah D Proctor; Nancy S Redeker
Journal:  Dig Dis Sci       Date:  2020-03-19       Impact factor: 3.199

9.  The effect of bifid triple viable on immune function of patients with ulcerative colitis.

Authors:  Guohua Li; Sheng Zeng; Wangdi Liao; Nonghua Lv
Journal:  Gastroenterol Res Pract       Date:  2012-08-15       Impact factor: 2.260

10.  Correlation of endoscopic disease severity with pediatric ulcerative colitis activity index score in children and young adults with ulcerative colitis.

Authors:  Basavaraj Kerur; Heather J Litman; Julia Bender Stern; Sarah Weber; Jenifer R Lightdale; Paul A Rufo; Athos Bousvaros
Journal:  World J Gastroenterol       Date:  2017-05-14       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.